id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0862-0006,FDA,FDA-2025-E-0862,Determination of Regulatory Review Period for Purposes of Patent Extension; SYMVESS,Notice,Determinations,2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,2026-04-21T03:59:59Z,2026-02-19T20:54:45Z,2026-03312,1,0,09000064b91bd33f
FDA-2025-E-0862-0005,FDA,FDA-2025-E-0862,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-11-25T05:00:00Z,2025,11,2025-11-25T05:00:00Z,,2025-11-25T17:17:32Z,,0,0,09000064b909552f
FDA-2025-E-0862-0004,FDA,FDA-2025-E-0862,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-09-11T04:00:00Z,2025,9,2025-09-11T04:00:00Z,,2025-09-11T17:22:25Z,,0,0,09000064b8f528ed
FDA-2025-E-0862-0003,FDA,FDA-2025-E-0862,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-06-30T04:00:00Z,2025,6,2025-06-30T04:00:00Z,,2025-06-30T20:30:01Z,,0,0,09000064b8e4576b
FDA-2025-E-0862-0002,FDA,FDA-2025-E-0862,"Patent Extension Application from Cooley LLP (on behalf of Humacyte Global, Inc)",Other,Application,2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T11:42:07Z,,0,0,0900006486a2990c
FDA-2025-E-0862-0001,FDA,FDA-2025-E-0862,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T11:41:49Z,,0,0,0900006486a293f6